Compare LCID & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | ACAD |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2020 | 2000 |
| Metric | LCID | ACAD |
|---|---|---|
| Price | $9.91 | $20.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 22 |
| Target Price | $20.20 | ★ $30.45 |
| AVG Volume (30 Days) | ★ 5.9M | 1.6M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | $595,271,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $78.31 | $18.52 |
| Revenue Next Year | $101.66 | $11.34 |
| P/E Ratio | ★ N/A | $9.25 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $1.97 | $14.08 |
| 52 Week High | $25.22 | $28.35 |
| Indicator | LCID | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 32.66 |
| Support Level | $9.38 | $20.62 |
| Resistance Level | $10.70 | $22.75 |
| Average True Range (ATR) | 0.59 | 1.04 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 33.05 | 0.00 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.